EDP Sciences logo
Subscriber Authentication Point
Rechercher
Menu
Accueil Tous les numéros Volume 42 / Numéro 6-7 (Juin-Juillet 2026) Med Sci (Paris), 42 6-7 (2026) 600-607 References
Issue
Med Sci (Paris)
Volume 42, Number 6-7, Juin-Juillet 2026
Agrégation protéique : aux sources des maladies neurodégénératives
Page(s) 600 - 607
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2026095
Published online 17 juillet 2026
  1. Heemels MT. Neurodegenerative diseases. Nature 2016; 539 : 179. [Google Scholar]
  2. Cerri S, Mus L, Blandini F. Parkinson’s disease in women and men: what’s the difference? J Parkinsons Dis 2019; 9 : 501–15. [Google Scholar]
  3. Bezard E, Dehay B. Maladie de Parkinson. Med Sci (Paris) 2022; 38 : 45–51. [Google Scholar]
  4. Brás IC, Dominguez-Meijide A, Gerhardt E, et al. Synucleinopathies: where we are and where we need to go. J Neurochem 2020; 153 : 433–54. [Google Scholar]
  5. Gomperts SN. Lewy Body Dementias: Dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneapolis, Minn) 2016; 22 : 435–63. [Google Scholar]
  6. Goh YY, Saunders E, Pavey S, et al. Multiple system atrophy. Prac Neurol 2023; 23 : 208–21. [Google Scholar]
  7. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol 2021; 20 : 385–97. [Google Scholar]
  8. Atik A, Stewart T, Zhang J. Alpha-Synuclein as a biomarker for Parkinson’s disease. Brain Pathol 2016; 26 : 410–8. [Google Scholar]
  9. Liu M, Wang Z, Shang H. Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials. J Neurol 2024; 271 : 2324–44. [Google Scholar]
  10. Dong L, Zhou R, Zhou J, et al. Positron emission tomography molecular imaging for pathological visualization in multiple system atrophy. Neurobio of Dis 2025; 206 : 106828. [Google Scholar]
  11. Goldman JG, Goetz CG, Brandabur M, et al. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008; 23 : 2248–50. [Google Scholar]
  12. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216 : 136–44. [CrossRef] [PubMed] [Google Scholar]
  13. Crozet C, Lehmann S. Les prions. Med Sci (Paris) 2007; 23 : 1148–58. [Google Scholar]
  14. Moudjou M, Ermonval M. Le phénomène Prion, différents aspects d’un nouveau concept en biologie. Virologie 2010; 14 : 255–68. [Google Scholar]
  15. Coste J, Prowse C, Eglin R, et al. A report on transmissible spongiform encephalopathies and transfusion safety. Vox Sang 2009; 96 : 284–91. [Google Scholar]
  16. Coste J. An overview of the diagnostic tools. Transfus Clin Biol 2013; 20 : 412–5. [Google Scholar]
  17. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001; 411 : 810–3. [Google Scholar]
  18. Thomas CM, Salamat MKF, Almela F, et al. Longitudinal detection of prion infection in preclinical sheep blood samples compared using 3 assays. Blood 2024; 144 : 1962–73. [Google Scholar]
  19. Bougard D, Brandel JP, Belondrade M, et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl Med 2016; 8 : 370ra182. [Google Scholar]
  20. Bougard D, Belondrade M, Mayran C, et al. Diagnosis of methionine/valine variant Creutzfeldt-Jakob disease by protein misfolding cyclic amplification. Emerg Infect Dis 2018; 24 : 1364–6. [Google Scholar]
  21. Brandel JP, Vlaicu MB, Culeux A, et al. Variant Creutzfeldt-Jakob disease diagnosed 7.5 years after occupational exposure. N Engl J Med 2020; 383 : 83–5. [Google Scholar]
  22. Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 2011; 17 : 175–8. [Google Scholar]
  23. Orru CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med 2014; 371 : 519–29. [Google Scholar]
  24. McKenzie N, Piconi G, Culeux A, et al. Concordance of cerebrospinal fluid real-time quaking-induced conversion across the European Creutzfeldt-Jakob Disease Surveillance Network. Eur J Neurol 2022; 29 : 2431–8. [Google Scholar]
  25. Hermann P, Appleby B, Brandel JP, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 2021; 20 : 235–46. [Google Scholar]
  26. Sargent D, Baron T. Assemblages d’alpha-synucléine. Med Sci (Paris) 2016; 32 : 233–6. [Google Scholar]
  27. Prusiner SB, Woerman AL, Mordes DA, et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A 2015; 112 : E5308–17. [Google Scholar]
  28. Nicot S, Verchere J, Belondrade M, et al. Seeded propagation of alpha-synuclein aggregation in mouse brain using protein misfolding cyclic amplification. FASEB J 2019; 33 : 12073–86. [Google Scholar]
  29. Betemps D, Arsac JN, Nicot S, et al. Protease-sensitive and -resistant forms of human and murine alpha-synucleins in distinct brain regions of transgenic mice (M83) expressing the human mutated A53T protein. Biomolecules 2023; 13. [Google Scholar]
  30. Bruyere-Ostells L, Verchere J, Betemps D, et al. Subclinical detection of misfolded alpha-synuclein in the blood of M83 mice. Acta Neuropathol 2025; 150 : 2. [Google Scholar]
  31. Van der Perren A, Gelders G, Fenyi A, et al. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol 2020; 139 : 977–1000. [Google Scholar]
  32. Fenyi A, Leclair-Visonneau L, Clairembault T, et al. Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification. Neurobiol Dis 2019; 129 : 38–43. [Google Scholar]
  33. Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 2016; 3 : 812–8. [Google Scholar]
  34. Shahnawaz M, Tokuda T, Waragai M, et al. Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 2017; 74 : 163–72. [Google Scholar]
  35. Groveman BR, Orrù CD, Hughson AG, et al. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathol Commun 2018; 6 : 7. [Google Scholar]
  36. Rossi M, Baiardi S, Teunissen CE, et al. Diagnostic value of the CSF alpha-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies. Neurology 2021; 97 : e930–e40. [Google Scholar]
  37. Shahnawaz M, Mukherjee A, Pritzkow S, et al. Discriminating alpha-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 2020; 578 : 273–7. [Google Scholar]
  38. Bernhardt AM, Longen S, Trossbach SV, et al. A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease. Acta Neuropathol 2025; 149 : 20. [Google Scholar]
  39. Wang Z, Becker K, Donadio V, et al. Skin α-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol 2021; 78 : 30–40. [Google Scholar]
  40. Vascellari S, Orru CD, Groveman BR, et al. alpha-Synuclein seeding activity in duodenum biopsies from Parkinson’s disease patients. PLoS Pathog 2023; 19 : e1011456. [Google Scholar]
  41. Bargar C, De Luca CMG, Devigili G, et al. Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Mol Neurodegener 2021; 16 : 82. [Google Scholar]
  42. Kluge A, Bunk J, Schaeffer E, et al. Detection of neuron-derived pathological alpha-synuclein in blood. Brain 2022; 145 : 3058–71. [Google Scholar]
  43. Kluge A, Schaeffer E, Bunk J, et al. Detecting Misfolded α-synuclein in blood years before the diagnosis of Parkinson’s disease. Movement Disorders 2024; 39 : 1289–99. [Google Scholar]
  44. Okuzumi A, Hatano T, Matsumoto G, et al. Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 2023; 29 : 1448–55. [Google Scholar]
  45. Rossi M, Farris CM, Baiardi S, et al. Comparison of two alpha-synuclein seed amplification assays for discrimination of Parkinson disease and atypical Parkinsonism. Mov Disord 2025. [Google Scholar]
  46. Soto C. alpha-Synuclein seed amplification technology for Parkinson’s disease and related synucleinopathies. Trends Biotechnol 2024; 42 : 829–41. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.